Evidence map›Paper›PMID 27648810›Full record

ArticleThe ISME journal2017

Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis.

Marlies Meisel, Toufic Mayassi, Hannah Fehlner-Peach, Jason C Koval, Sarah L O'Brien, Reinhard Hinterleitner, Kathryn Lesko, Sangman Kim, Romain Bouziat, Li Chen and 4 more

Abstract read
In one paragraph

Article in The ISME journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Bibliometric analysis of theFrontiers in microbiology · 2025
    Pooled it
  2. Article
  3. Article
  4. Gut microbes · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marlies MeiselDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Toufic MayassiDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Hannah Fehlner-PeachDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Jason C KovalBiosciences Division, Argonne National Laboratory, Argonne, IL, USA.
Sarah L O'BrienBiosciences Division, Argonne National Laboratory, Argonne, IL, USA.
Reinhard HinterleitnerDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Kathryn LeskoDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Sangman KimDepartment of Medicine, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-8204-0393
Romain BouziatDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Li ChenDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Christopher R WeberDepartment of Pathology, The University of Chicago, Chicago, IL, USA.
Sarkis K MazmanianDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Bana JabriDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Dionysios A AntonopoulosDepartment of Medicine, The University of Chicago, Chicago, IL, USA.

Funding

ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 1990 to 2025
$29.8M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007090 · NIAID · UNIVERSITY OF CHICAGO · PI Peter Aidan Savage · 1985 to 2026
$11.7M
Innate and adaptive immunity in celiac diseaseR01DK067180 · NIDDK · UNIVERSITY OF CHICAGO · PI JABRI, BANA · 2005 to 2024
$8.5M
Protection from Mucosal Pathology by Gut Microflora during Experimental ColitisR01DK078938 · NIDDK · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI MAZMANIAN, SARKIS K · 2009 to 2020
$5.1M
NIAID NIH HHS T32 AI007090NIDDK NIH HHS P30 DK042086NIDDK NIH HHS R01 DK067180NIDDK NIH HHS R01 DK078938
6 · The paper itself

Abstract

Dysbiosis resulting in gut-microbiome alterations with reduced butyrate production are thought to disrupt intestinal immune homeostasis and promote complex immune disorders. However, whether and how dysbiosis develops before the onset of overt pathology remains poorly defined. Interleukin-15 (IL-15) is upregulated in distressed tissue and its overexpression is thought to predispose susceptible individuals to and have a role in the pathogenesis of celiac disease and inflammatory bowel disease (IBD). Although the immunological roles of IL-15 have been largely studied, its potential impact on the microbiota remains unexplored. Analysis of 16S ribosomal RNA-based inventories of bacterial communities in mice overexpressing IL-15 in the intestinal epithelium (villin-IL-15 transgenic (v-IL-15tg) mice) shows distinct changes in the composition of the intestinal bacteria. Although some alterations are specific to individual intestinal compartments, others are found across the ileum, cecum and feces. In particular, IL-15 overexpression restructures the composition of the microbiota with a decrease in butyrate-producing bacteria that is associated with a reduction in luminal butyrate levels across all intestinal compartments. Fecal microbiota transplant experiments of wild-type and v-IL-15tg microbiota into germ-free mice further indicate that diminishing butyrate concentration observed in the intestinal lumen of v-IL-15tg mice is the result of intrinsic alterations in the microbiota induced by IL-15. This reconfiguration of the microbiota is associated with increased susceptibility to dextran sodium sulfate-induced colitis. Altogether, this study reveals that IL-15 impacts butyrate-producing bacteria and lowers butyrate levels in the absence of overt pathology, which represent events that precede and promote intestinal inflammatory diseases.

Indexed as

Gastrointestinal MicrobiomeAnimalsBacteriaButyratesColitisDisease SusceptibilityDysbiosisFecal Microbiota TransplantationFecesFemaleGerm-Free LifeHumansInterleukin-15Intestinal MucosaIntestinesMaleButyratesInterleukin-15

Identifiers

PMID27648810
PMCPMC5315477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.